Outlook Therapeutics (OTLK) Finished Goods (2025 - 2026)
Outlook Therapeutics (OTLK) reported Finished Goods of $201903.0 for Q1 2026, down 93.94% year-over-year from $3.3 million in Q1 2025, and up 581.51% quarter-over-quarter from $29626.0 in Q3 2025.
Outlook Therapeutics (OTLK) Finished Goods (2025 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 2 years of Finished Goods data on file, last reported at $201903.0 in Q1 2026.
- Finished Goods for Q1 2026 came in at $201903.0, down 93.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $201903.0 (down 93.94% YoY), and the FY2025 annual result was $29626.0, changed N/A from the prior year.
- Finished Goods rose to $201903.0 in Q1 2026 per OTLK's latest filing, from $29626.0 in the prior quarter.
- Over five years, Finished Goods peaked at $3.3 million in Q1 2025 and troughed at $29626.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 201,903.00 |
| Sep 30, 2025 | 29,626.00 |
| Jun 30, 2025 | 377,223.00 |
| Mar 31, 2025 | 3.33 Mn |